Acute kidney injury in patients with cancer receiving anti-PD-1/PD-L1 antibodies: incidence, risk factors, and prognosis

Anti-PD-1/PD-L1 antibodies are widely used in anti-cancer therapy. While they have improved cancer prognoses, immune-related adverse events, which can cause acute kidney injury (AKI), cannot be ignored. The purpose of this retrospective cohort study was to assess the incidence, risk factors, and pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Lou, Qianqian, Gong, Jianguang, Ye, Binxian, Yu, Rizhen, Bu, Shuangshan, Li, Yiwen, Zhu, Bin, Shao, Lina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373620/
https://www.ncbi.nlm.nih.gov/pubmed/37491871
http://dx.doi.org/10.1080/0886022X.2023.2238823

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373620/
https://www.ncbi.nlm.nih.gov/pubmed/37491871
http://dx.doi.org/10.1080/0886022X.2023.2238823

Ejemplares similares